88491-61-6 Usage
Description
3-Bromopyridine can undergo lithiation with LDA at low temperatures in the 4-position: Heterocycles, involved in formation of the Grignard by Mg exchange with i-PrMgCl and in transmetallation of the lithiated derivative with zinc chloride followed by treatment with an electrophile as a route to 4-substituted 3-bromopyridines1-4. 3-Bromopyridine is also used as an intermediate in the synthesis of Active Pharmaceutical Ingredients especially Abiraterone acetate (an antiandrogen medication which is used in the treatment of prostate cancer) and Zimelidine (selective serotonin reuptake inhibitor (SSRI) antidepressants)5.
References
Jennifer A. Love Dr.; John P. Morgan.;Tina M. Trnka.;Robert H. Grubbs Prof. A Practical and Highly Active Ruthenium-Based Catalyst that Effects the Cross Metathesis of Acrylonitrile. Angewandte Chemie International Edition. 2002, 41 (21), 4035-4037.
Wenjie Li.; Dorian P. Nelson.; Mark S. Jensen.; R. Scott Hoerrner.; Dongwei Cai.; Robert D. Larsen.; Paul J. Reider. An Improved Protocol for the Preparation of 3-Pyridyland Some Arylboronic Acids. J. Org. Chem. 2002, 57 (16), 5394-5397.
https://www.alfa.com/en/catalog/A12894/
Cai, Dongwei, R. D. Larsen, and P. J. Reider. "Effective lithiation of 3-bromopyridine: synthesis of 3-pyridine boronic acid and variously 3-substituted pyridines." Cheminform 33.38(2002):4285-4287.
www.jubl.com/uploads/files/48msds_msds-3-bromopyridine.pdf
Check Digit Verification of cas no
The CAS Registry Mumber 88491-61-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,8,4,9 and 1 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 88491-61:
(7*8)+(6*8)+(5*4)+(4*9)+(3*1)+(2*6)+(1*1)=176
176 % 10 = 6
So 88491-61-6 is a valid CAS Registry Number.
InChI:InChI=1/C4H3BrN2/c5-4-2-1-3-6-7-4/h1-3H
88491-61-6Relevant articles and documents
3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I
-
Page/Page column 68, (2015/11/16)
The invention relates to amidic oxotetrahydro-2H-furo[3.2-b]pyrrol-4(5H)-yl) derivatives as dual CatS/K inhibitors, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
